Blood Vessel Changes in Tauopathy

Rachel Bennett, PhD
Massachusetts General Hospital, Harvard Medical School (Boston, MA)

Co-Principal Investigators

Bradley Hyman, MD, PhD
Massachusetts General Hospital
Year Awarded:
2016
Grant Duration:
July 1, 2016 to June 30, 2018
Disease:
Alzheimer's Disease
Award Amount:
$100,000
Grant Reference ID:
A2016404F
Award Type:
Postdoctoral Fellowship
Award Region:
US Northeastern
Dr. Rachel Bennett

Blood Vessel Changes in Tauopathy

Summary

We have observed that tau, a key player in Alzheimer’s disease (AD), leads to blood vessel changes and increased expression of proteins involved in new blood vessel growth in the brains of mice. We do not know if these changes contribute to cell death and accumulation of AD proteins. This research aims to determine if blood vessel alterations are an early or late event in the disease process and to use “off the shelf” drugs to prevent blood vessel growth. Altogether, these studies will determine if the observed changes are harmful and may point towards widely available treatment options that should be considered for Alzheimer’s disease patients.

Details

Our research goals are twofold 1) determine if these tau-induced vascular changes contribute to cell death and further pathological accumulation of tau and 2) test whether therapeutic interventions to prevent blood vessel changes can alter the disease course.

To achieve these goals, our laboratory is using two well-characterized mouse models of Alzheimer's disease in addition to cutting-edge microscopy techniques for visualizing alterations to vasculature in the intact, living brain.  Initial studies are aimed at understanding when blood vessel alterations occur and how changes relate to Alzheimer's disease pathology.  We are also profiling the expression of proteins involved in blood vessel growth to identify potential new targets for therapeutics.  Based on this new understanding of the relationship between tau and blood vessels, we aim to use "off the shelf" drugs to alter blood vessel growth and directly assess their effect on pathological outcomes in these models.

These studies are unique in that they examine a novel and previously unexplored interaction between tau pathology and blood vessels. Altogether, this research will determine if the observed blood vessel changes are harmful and may point towards widely-available therapeutic options to treat Alzheimer’s disease patients.

About the Researcher

Rachel Bennett, Ph.D., completed her bachelor's degree in Molecular Biosciences and Biotechnology at Arizona State University in 2007.  She then went on to perform her graduate studies in Neurosciences at Washington University of St. Louis under the mentorship of Dr. David Brody. For her thesis, she examined interactions between the immune system and neuronal damage in traumatic brain injury.  In 2014, she joined the Alzheimer's research laboratory of Dr. Bradley Hyman at Massachusetts General Hospital where she continues to pursue long-standing interests in mechanisms of neurodegeneration and in vivo imaging methods as a post-doctoral fellow.

Personal Story

I am deeply grateful to the BrightFocus donors who have made this research possible.  By funding these studies, we have the resources to thoroughly investigate this exciting new line of research.  I truly believe that the exploration of new disease pathways is critical to the advancement of Alzheimer's disease research as a field and hope that it will lead to the identification of novel drug candidates.  Thank you for your generous support.

Publications

Bennett RE, Robbins AB, Hu M, Cao X, Betensky RA, Clark T, Das S, Hyman BT. Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A. 2018 Jan 22. pii: 201710329. doi: 10.1073/pnas.1710329115. [Epub ahead of print] PubMed Icon Google Scholar Icon
 

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.